Chemokine polymorphisms and lymphoma: a pooled analysis

Abstract

Polymorphisms in chemokine genes have been associated with human immunodeficiency virus (HIV)-related non-Hodgkin lymphoma (NHL) but are understudied in non-HIV-related NHL. Associations of NHL and NHL subtypes with polymorphisms and haplotypes in CCR5, CCR2, CCL5, CXCL12, and CX₃CR₁ were explored in a pooled analysis of three case–control studies (San Francisco Bay Area, California; United Kingdom; total: cases N = 1610, controls N = 1992). Adjusted unconditional logistic regression was used to estimate relative risks among HIV-negative non-Hispanic Caucasians. The CCR5 Δ32 deletion reduced the risk of NHL (odds ratio = 0.56, 95% confidence interval = 0.38–0.83) in men but not women with similar effects observed for diffuse large-cell and follicular lymphoma (FL). NHL risk also was reduced in men with the CCR2/CCR5 haplotype characterized by the CCR5 Δ32 deletion. The CCL5 -403A allele conferred reduced risks of FL and chronic lymphocytic leukemia/small lymphocytic lymphoma. Results should be interpreted conservatively. Continued investigation is warranted to confirm these findings.

Keywords:

• Lymphoma non-Hodgkin
• chemokines
• polymorphism
• genetic
• case–control

Declaration of interest: This study was funded by grants CA45614, CA104862, and CA122663 and in part by grants CA89745 and CA87014 from the National Cancer Institute, National Institutes of Health (NHL1 and NHL2 studies), and Leukaemia Research of Great Britain (UK study).